Furthermore, Transwell assays revealed that both niclosamide treatment and YTHDF2 knockdown (YTHDF2-KD) diminished cell migration and invasion capabilities, suggesting that niclosamide may impede gastric cancer metastasis (Figures 7K and 7L). Here, YTHDF2 is linked to gastric cancer.